For decades, pharmaceutical companies and their allies within regulatory bodies have systematically suppressed scientific evidence about dimethyl sulfoxide (DMSO)—a natural compound derived from trees with documented tissue regeneration, inflammation reduction, and chronic pain relief capabilities. According to the text, DMSO has been the subject of over 11,000 scientific studies since the 1960s but has been buried under false safety claims by major drug manufacturers due to its non-patentable nature and threat to profit from toxic chemotherapy, opioids, and synthetic pharmaceuticals.

Veterinarians and sports medicine professionals have utilized DMSO for decades without adverse effects to treat racehorses, athletes, and chronic pain conditions. However, the U.S. Food and Drug Administration (FDA) restricts its human use while approving high-risk medications that generate billions in profits for the pharmaceutical industry. The text highlights a 2014 study in Cancer Letters demonstrating DMSO’s ability to induce cancer cell apoptosis when combined with hematoxylin—a finding allegedly suppressed due to its potential to undermine chemotherapy and radiation treatments.

DMSO functions as a polar solvent capable of transporting therapeutic compounds into tissues, exhibits potent anti-inflammatory properties, and stimulates the body’s natural regenerative processes through stem cell activation and neuroplasticity. Despite decades of research documenting its non-toxic and non-addictive nature, the FDA continues to block its widespread human application while prioritizing the distribution of opioids and chemotherapy agents that cause severe patient harm.

The text asserts that pharmaceutical interests have historically targeted DMSO since the 1960s, launching campaigns falsely claiming it caused eye damage in rabbits—a claim later debunked—simply because it outperformed conventional treatments at significantly lower costs. Current suppression efforts persist, with industry leaders actively blocking access to this natural compound despite its proven efficacy in veterinary and clinical settings.